Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Duddy

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
JAMA Neurology|November 14, 2017
Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG DiseaseShahd H M Hamid, Dan Whittam, Mariyam Saviour, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 23, 2018
Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing schemeJacqueline Palace, Martin Duddy, Michael Lawton, et al.
Multiple Sclerosis and Related Disorders|May 19, 2021
COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapiesAfagh Garjani, Rodden M Middleton, Rachael Hunter, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 29, 2020
Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS RegisterNikos Evangelou, Afagh Garjani, Roshan dasNair, et al.
Annals of Neurology|March 7, 2013
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantationPeter J Darlington, Tarik Touil, Jean-Sebastien Doucet, et al.
Brain : a Journal of Neurology|October 8, 2021
The impact of smoking cessation on multiple sclerosis disease progressionJeff Rodgers, Tim Friede, Frederick W Vonberg, et al.
BMJ Neurology Open|September 12, 2024
Brain reserve and physical disability in secondary progressive multiple sclerosisNevin John, Yingtong Li, Floriana De Angelis, et al.
Lancet (London, England)|October 4, 2025
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trialJeremy Chataway, Thomas Williams, James Blackstone, et al.
BMJ Open|September 16, 2024
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UKJames Blackstone, Thomas Williams, Jennifer M Nicholas, et al.
Health Technology Assessment (Winchester, England)|June 29, 2026
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trialThomas Williams, James Blackstone, Nevin John, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
JAMA Neurology|November 14, 2017
Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG DiseaseShahd H M Hamid, Dan Whittam, Mariyam Saviour, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 23, 2018
Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing schemeJacqueline Palace, Martin Duddy, Michael Lawton, et al.
Multiple Sclerosis and Related Disorders|May 19, 2021
COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapiesAfagh Garjani, Rodden M Middleton, Rachael Hunter, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 29, 2020
Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS RegisterNikos Evangelou, Afagh Garjani, Roshan dasNair, et al.
Annals of Neurology|March 7, 2013
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantationPeter J Darlington, Tarik Touil, Jean-Sebastien Doucet, et al.
Brain : a Journal of Neurology|October 8, 2021
The impact of smoking cessation on multiple sclerosis disease progressionJeff Rodgers, Tim Friede, Frederick W Vonberg, et al.
BMJ Neurology Open|September 12, 2024
Brain reserve and physical disability in secondary progressive multiple sclerosisNevin John, Yingtong Li, Floriana De Angelis, et al.
Lancet (London, England)|October 4, 2025
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trialJeremy Chataway, Thomas Williams, James Blackstone, et al.
BMJ Open|September 16, 2024
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UKJames Blackstone, Thomas Williams, Jennifer M Nicholas, et al.
Health Technology Assessment (Winchester, England)|June 29, 2026
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trialThomas Williams, James Blackstone, Nevin John, et al.
Pageof 5